Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Marc W, Retter"'
Autor:
Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith, Marc W. Retter
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 954-966 (2022)
Abstract Odronextamab is a fully‐human IgG4‐based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T‐cell‐mediated cytotoxicity independent of T‐cell‐receptor recognition. Adequate safety, tolerabi
Externí odkaz:
https://doaj.org/article/a445f9bfc75148d9ba23acb3770e8acf
Autor:
Lauric Haber, Kara Olson, Marcus P. Kelly, Alison Crawford, David J. DiLillo, Richard Tavaré, Erica Ullman, Shu Mao, Lauren Canova, Olga Sineshchekova, Jennifer Finney, Arpita Pawashe, Supriya Patel, Ryan McKay, Sahar Rizvi, Ermelinda Damko, Danica Chiu, Kristin Vazzana, Priyanka Ram, Katja Mohrs, Amanda D’Orvilliers, Jenny Xiao, Sosina Makonnen, Carlos Hickey, Cody Arnold, Jason Giurleo, Ya Ping Chen, Courtney Thwaites, Drew Dudgeon, Kevin Bray, Ashique Rafique, Tammy Huang, Frank Delfino, Aynur Hermann, Jessica R. Kirshner, Marc W. Retter, Robert Babb, Douglas MacDonald, Gang Chen, William C. Olson, Gavin Thurston, Samuel Davis, John C. Lin, Eric Smith
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
Abstract T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing of tumo
Externí odkaz:
https://doaj.org/article/13db8e3e17e043ffbbadbbb6bb988d63
Autor:
Kishor Devalaraja-Narashimha, Cong Huang, Marc Cao, Ya Ping Chen, Anna Borodovsky, William C Olson, Lori G Morton, Marc W Retter
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0269749 (2022)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease caused by uncontrolled complement activation; effective and approved treatments include terminal complement inhibition. This study assessed whether combination cemdisiran (an investigational
Externí odkaz:
https://doaj.org/article/8865305a9d93438b9a993741d6cbf071
Autor:
Gavin Thurston, Richard Tavare, Marcus P Kelly, Sosina Makonnen, Carlos Hickey, T Cody Arnold, Jason T Giurleo, Makenzie Danton, Christian Granados, Ishita Chatterjee, Drew Dudgeon, Marc W Retter, Dangshe Ma, William C Olson, Jessica R Kirshner
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types. Tumorous PD-L1 expression, as assessed by immunohistoche
Externí odkaz:
https://doaj.org/article/95ca884fb1ff45408c623ba0079af2dc
Autor:
Adrianna Latuszek, Yashu Liu, Olav Olsen, Randi Foster, Marc Cao, Irena Lovric, Ming Yuan, Nina Liu, Henry Chen, Qian Zhang, Hui Xiao, Carola Springer, George Ehrlich, Vishal Kamat, Ashique Rafique, Ying Hu, Pamela Krueger, Tammy Huang, William Poueymirou, Robert Babb, Michael P Rosconi, Marc W Retter, Gang Chen, Lori Morton, Brian Zambrowicz, Jingtai Cao, Carmelo Romano, William C Olson
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0231892 (2020)
Complement is a key component of the innate immune system. Inappropriate complement activation underlies the pathophysiology of a variety of diseases. Complement component 5 (C5) is a validated therapeutic target for complement-mediated diseases, but
Externí odkaz:
https://doaj.org/article/050c7eb8e3d948eab37777fb62eda2e6
Autor:
John O. DaSilva, Frank Delfino, Arthur Kunz, Randi Foster, Marc W. Retter, Jason T. Giurleo, Sosina Makonnen, Marcus Kelly, Shu Mao, Zhaoyuan Chen, Rabih Slim, Tara M. Young, Thomas Nittoli, William C. Olson, Feng Zhao, Matthew C. Franklin, Oliver Surriga, Katie Yang, Pamela Krueger, Christopher Daly, Carlos Hickey, Gavin Thurston
Publikováno v:
Molecular Cancer Therapeutics. 20:1966-1976
Lung cancers harboring mesenchymal-to-epithelial transition factor (MET) genetic alterations, such as exon 14 skipping mutations or high-level gene amplification, respond well to MET-selective tyrosine kinase inhibitors (TKI). However, these agents b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d6e8736c87f6f2e556c3b466b9e693
https://doi.org/10.1158/1535-7163.mct-21-0009
https://doi.org/10.1158/1535-7163.mct-21-0009
Autor:
William C. Olson, Alison Crawford, Kara Olson, Jennifer Finney, Ashique Rafique, Kristin Vazzana, Drew Dudgeon, Cody Arnold, Lauren Canova, Eric Smith, Samuel Davis, Gavin Thurston, Ryan McKay, Tammy T. Huang, Danica Chiu, Douglas MacDonald, Sahar Rizvi, Robert Babb, Richard Tavaré, Amanda Dorvilliers, Erica Ullman, Arpita Pawashe, Shu Mao, Ya Ping Chen, Sosina Makonnen, Jenny Xiao, Lauric Haber, Jessica R. Kirshner, Aynur Hermann, Marcus Kelly, Gang Chen, Bray Kevin A, Courtney Thwaites, Carlos Hickey, Olga Sineshchekova, Katja Mohrs, Jason T. Giurleo, Ermelinda Damko, Supriya Patel, John C. Lin, Frank Delfino, Marc W. Retter, Priyanka Ram, Dilillo David
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
Scientific Reports
Scientific Reports
T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing of tumor cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c594174da440faa66c488c86be8e9c2
https://doaj.org/article/13db8e3e17e043ffbbadbbb6bb988d63
https://doaj.org/article/13db8e3e17e043ffbbadbbb6bb988d63
Autor:
Jessica Kuhnert, Kara Olson, Thomas Startz, Jessica R. Kirshner, Gavin Thurston, Marc W. Retter, Stephen Godin, Dilillo David, Katja Mohrs, Prachi Sharma, Eric Smith, John C. Lin, Olga Sineshchekova, Meagher Thomas Craig, Frank Delfino, Bray Kevin A
Publikováno v:
Blood Adv
CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a1a5b8db855f5e1b9e5b61a5dd659c
https://doi.org/10.1182/bloodadvances.2020002736
https://doi.org/10.1182/bloodadvances.2020002736
Autor:
Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith, Marc W. Retter
Publikováno v:
Clinical and translational science. 15(4)
Odronextamab is a fully-human IgG4-based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T-cell-mediated cytotoxicity independent of T-cell-receptor recognition. Adequate safety, tolerability, and encouraging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e4f49640cf6d953b90535316e8e592
https://pubmed.ncbi.nlm.nih.gov/34997701
https://pubmed.ncbi.nlm.nih.gov/34997701
Autor:
Irena Lovric, Hui Xiao, Jingtai Cao, Brian Zambrowicz, Carola Springer, Olav Olsen, Vishal Kamat, Marc W. Retter, Ming Yuan, Ashique Rafique, Ying Hu, George Ehrlich, Yashu Liu, William C. Olson, Carmelo Romano, Randi Foster, Pamela Krueger, Nina Liu, Henry Chen, William Poueymirou, Qian Zhang, Michael P. Rosconi, Morton Lori C, Marc Cao, Gang Chen, Robert Babb, Adrianna Latuszek, Tammy T. Huang
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0231892 (2020)
PLoS ONE
PLoS ONE
Complement is a key component of the innate immune system. Inappropriate complement activation underlies the pathophysiology of a variety of diseases. Complement component 5 (C5) is a validated therapeutic target for complement-mediated diseases, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e67a14314ecd3b03b580d43c5072a1
https://doaj.org/article/050c7eb8e3d948eab37777fb62eda2e6
https://doaj.org/article/050c7eb8e3d948eab37777fb62eda2e6